What is the Effect of Monjauro Weight Loss Treatment on Hair Fall and How Does It Affect PRP Treatments?

The emergence of GLP-1 receptor agonists such as Monjauro (tirzepatide) has revolutionised weight loss therapy, offering unprecedented results for individuals struggling with obesity and metabolic disease. While Monjauro has proven highly effective in improving health outcomes, one of the increasingly recognised side effects is hair loss, which can complicate the management of those already dealing with conditions such as male and female pattern hair loss. At Rejuvence Clinic, where we specialise in advanced regenerative hair treatments, this is an important concern we frequently address with our patients.

 

Research from recent pharmacovigilance studies has shown that Monjauro can be associated with hair loss, most commonly in the form of telogen effluvium, a condition where hair follicles prematurely enter the shedding phase. The mechanism is likely multifactorial. First, rapid weight loss itself is a well-recognised trigger for shedding, as the body prioritises essential metabolic functions over hair growth. Secondly, appetite suppression and dietary restriction caused by Monjauro can lead to nutritional deficiencies in iron, zinc, vitamin D, and protein — all vital for healthy follicles. Finally, hormonal and inflammatory changes linked to GLP-1 agonists may play a role, although interestingly, some studies suggest that long-term metabolic and inflammatory improvements may benefit hair in the longer term once shedding stabilises.

 

From a PRP perspective, there is no evidence that Monjauro directly interferes with the regenerative mechanisms of platelet-rich plasma therapy. PRP works by delivering growth factors such as VEGF, PDGF, and IGF-1 directly to the scalp, stimulating follicular regeneration and prolonging the growth phase of the hair cycle. However, patients taking Monjauro may experience indirect challenges that influence PRP outcomes, particularly in the early stages of treatment. These include temporary increases in hair shedding linked to rapid weight loss, as well as reduced follicular responsiveness if nutritional deficiencies develop. In our experience, PRP still works effectively for these patients, but timing and supportive measures are essential to maximise results.

 

At Rejuvence Clinic, we regularly see patients presenting with concerns related to hair changes after weight loss treatments such as Monjauro. From his personal experience, Dr Ghani recalls a patient with a history of polycystic ovarian syndrome who initially experienced significant hair loss along the middle parting in a classic “Christmas tree” distribution. With a combination of minoxidil, spironolactone, and Magellan TruPRP, her hair improved substantially, and this improvement was sustained for more than 12 months. However, after embarking on a course of Monjauro and achieving rapid weight loss, she unfortunately suffered a significant new phase of shedding.

 

In another case, Dr Ghani recalls a male patient who had consolidated an excellent 3,000 graft hair transplant performed abroad with ongoing PRP and topical minoxidil. His results were well maintained until he lost a considerable amount of weight over a six-month period while on Monjauro. This rapid weight reduction appeared to reactivate his underlying pattern hair loss, leading to new thinning and deterioration of his overall hair density despite the transplant.

 

These experiences underline an important reality: while weight loss and an active lifestyle are essential for health, quality of life, and longevity, there can be side effects, and hair shedding is one of the most visible and distressing. For patients using Monjauro, it is important to anticipate and plan for this possibility rather than being caught off guard.

 

At Rejuvence Clinic, we take a strategic and layered approach. Alongside advanced regenerative systems such as Magellan TruPRP and Angel Arthrex PRP, and our innovative autologous exosome therapy, we recommend medical treatments like minoxidil and finasteride for men, and minoxidil and spironolactone for women, to reinforce follicular strength during periods of stress. We also support patients with nutritional supplementation, such as Replenology, which has demonstrated sustained improvements in hair density at three and six months in published reviews, outperforming or matching products such as Nutrafol and Viviscal.

 

In summary, Monjauro is an effective and life-changing treatment for weight management, but it can be associated with phases of increased hair shedding. This does not mean that the benefits of weight loss should be overshadowed, but it does mean patients need to be prepared and proactive in protecting their hair health during this period of adjustment. At Rejuvence Clinic, we can help clients design tailored strategies to mitigate hair loss while supporting their weight-loss journey, ensuring that overall health improvements are not undermined by unwanted cosmetic concerns.

 

If you are taking Monjauro and are worried about hair loss, we invite you to book a consultation with us. Together, we can create a personalised and comprehensive hair restoration plan that works alongside your health goals.

 

📚 Key References

1. Godfrey, H., Leibovit-Reiben, Z., et al. (2025). Alopecia associated with semaglutide and tirzepatide: FDA adverse event reporting system (2022–2025). Journal of Dermatology.
2. Fattahi, A., Salako, K. (2025). Dermatological adverse reactions and therapeutic potential of GLP-1 receptor agonists: UK pharmacovigilance analysis. Authorea.
3. Rapparini, L., Pampaloni, F., et al. (2025). Benefit–risk assessment of GLP-1 receptor agonists: implications for dermatologists and plastic surgeons. Dermatology and Therapy.
4. Burke, O.M., Sa, B., Cespedes, D.A., Tosti, A. (2025). Dermatologic implications of GLP-1 receptor agonist medications. Skin Appendage Disorders.
5. Tassavor, B., Al Salem, S. (2025). Use of GLP-1 agonists in modulating preexisting dermatologic disease: systematic review. Cureus.
6. Ponce, M.B., Shields, B.E. (2025). Dermatologic implications of glycaemic control medications. Cutis.
7. Kushner, R.F., Johansen, O.E., et al. (2025). Symptomatic adverse events and quality of life in incretin-based medicines for obesity: review of >400,000 subjects. Obesities.
8. DeVore, S., Meihofer, A., Miner, K. (2025). Systematic review of cutaneous adverse effects of GLP-1 agonists. ResearchGate.